General practitioner examining a patient's hand for signs of rheumatoid arthritis. A breakthrough in cancer and autoimmune disease therapy could unlock a whole new frontier in medicine. Scientists are ...
ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to HIV-negative patients. The efficacy of immune checkpoint inhibitors was ...
The health of the thymus – a key part of the body’s immune system - is associated with cancer patients’ outcomes to immune ...
We conducted a prospective study of patients with solid tumors who received pembrolizumab or atezolizumab at the National Institute of Oncology, Rabat from July 2018 to December 2023. We identified ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced that the first patient has been dosed in its ...
mRNA vaccines can enhance immunotherapy efficacy by activating the immune system, improving outcomes in hard-to-treat tumors. mRNA COVID-19 vaccines enhance immune responses, improving cancer ...
Patients with immune checkpoint inhibitor colitis initially treated with high-dose glucocorticoids had a higher risk for rehospitalization than those treated with biologics, according to a study ...
A Japanese-led research team has developed AUN, a groundbreaking immune-independent bacterial cancer therapy that uses two ...
Review of current evidence indicates immune checkpoint inhibitors offer comparable efficacy and safety for NSCLC in people living with HIV, with no adverse impact on viral load or CD4 counts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback